Drug profile · INN
tildrakizumab
ILUMYA
tildrakizumab (ILUMYA) is a interleukin-23 inhibitor. Associated with Lacuna Pharma Pty Ltd.
EMA: approved TGA: approved Antineoplastic and immunomodulating agents (L04) L04AC
Patents linked 0
Pipeline programs 4
News articles 0
Drug details — tildrakizumab
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- —
- Patents
- 0
- Programs
- 4
- Data quality
- 0.89
Quick answer
tildrakizumab (ILUMYA) is a interleukin-23 inhibitor. Associated with Lacuna Pharma Pty Ltd.
Key facts
INN tildrakizumab
Brand ILUMYA
Mechanism Interleukin-23 inhibitor
Target Interleukin-23
Therapeutic class Antineoplastic and immunomodulating agents (L04)
ATC code L04AC
Originator Lacuna Pharma Pty Ltd
Mechanism of action
Interleukin-23 inhibitor
Primary target: Interleukin-23
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tildrakizumab?
tildrakizumab (ILUMYA) is a interleukin-23 inhibitor. Associated with Lacuna Pharma Pty Ltd.
What is the brand name for tildrakizumab?
ILUMYA is a marketed brand name for tildrakizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.